UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
Back to Urology at UCLA home It Begins With U

Urology at UCLA


UCLA Institute of Urologic Oncology

Welcome to the UCLA Institute of Urologic Oncology

UCLA's Institute of Urologic Oncology brings together a multidisciplinary team of scientists and physicians to develop leading-edge therapies for the treatment of prostate, kidney, bladder and testicular cancers. Disciplines include urologic oncology, medical oncology, diagnostic and interventional radiology, pathology, nursing, basic sciences and clinical trials.

Dr. Arie Belldegrun
Dr. Arie Belldegrun, Director of the UCLA Institute of Urologic Oncology
New IUO Website
New IUO Website
Visit the newly launched UCLA Institute of Urologic Oncology website »

"Our goal is to bring all our resources to the patient, rather than the patient going from office to office to see everyone they need to see" says urologist Arie Belldegrun, M.D., the institute's director and a researcher at UCLA's Jonsson Comprehensive Cancer Center.

Patients also benefit from the institute's top diagnostic tools, expertise in robotic and minimally invasive surgery and the combined experience of the experts, who often treat the most complicated urologic cancer cases. In addition, a joint, multidisciplinary board representing all genitourinary specialties meets at the institute to discuss complicated and challenging tumor cases referred to UCLA.

"With this approach, we are able to get leading-edge therapies to patients faster, taking them out of the lab and into practice in much less time," says Jean DeKernion, M.D., chair of the UCLA Department of Urology.

UCLA Launches new Institute of Urologic Oncology (March 2009) »

Why the Institute of Urologic Oncology at UCLA?

IUO Spotlight

New experimental test for prostate cancer more sensitive, specific than PSA test


Gang Zeng, PhD
Gang Zeng, PhD

By Kim Irwin May, 2011
A new test for prostate cancer that measures levels of prostate-specific antigen (PSA) as well as six specific antibodies found in the blood of men with the disease is more sensitive and more specific than the conventional PSA test used today, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.


The new test, called the A+PSA assay, also reduced the rate of false positives, tests that indicate the presence of cancer when no disease is actually present, said senior study author Gang Zeng, an associate professor of urology and a Jonsson Cancer Center researcher. "This is a very promising new approach," Zeng said. "Instead of using just one parameter, PSA, to test for prostate cancer, we use multiple parameters that can be measured in a single reaction."

View Webcast »

Story on newsroom.ucla.edu »

Video on KABC abclocal.go.com »

The IUO focuses the comprehensive resources available at UCLA on personalized, patient-centered treatment of urologic cancers and the development and delivery of new therapies. Patients can conveniently access the various specialists involved in their care, thereby simplifying the decision-making process for preferred treatment and improving their overall medical care.

This integrated approach allows experts from related disciplines to collaborate more efficiently and effectively to bring to patients the most promising advances in disease-centered, multi-specialty diagnosis and medical and surgical treatments—including molecular pathology, targeted therapies, chemotherapy, immunotherapy, radiation therapy, and minimally invasive and ablative surgery.

UCLA has been a pioneer in the multidisciplinary, translational approach to care, including targeted therapies; the development of novel, minimally invasive cancer surgeries and reconstructive surgical techniques offering improved quality of life; and the development of molecularly targeted drugs. Avastin, Sutent, Nexavar, Toricel, Afinitor, Abiraterone, MDR 3100, Herceptin, and Gleevec, among others, were developed in large part based on research conducted in the clinics and laboratories of UCLA’s Jonsson Comprehensive Cancer Center . Such leading-edge work to develop new, personalized, less toxic, and more-effective therapies for urologic cancers will be done within the IUO.

The IUO harnesses the collective expertise of specialists in urologic and medical oncology, diagnostic and interventional radiology, pathology, nursing, basic sciences, and clinical trials to advance the most innovative and integrated approaches to the prevention, diagnosis, and treatment of urologic cancers. Patients benefit from the combined experience of these doctors, who often treat the most complicated urologic cancer cases.

Meet our Expert Team
Our expert specialists at the UCLA Institute of Urologic Oncology »

UCLA Breaks Ground on Edie and Lew Wasserman Building

UCLA breaks ground on Edie and Lew Wasserman BuildingArtist's rendering of new Edie and Lew Wasserman Building (Shimahara Illustration/Richard Meier & Partners Architects)UCLA broke ground Oct. 14 on construction of the new Edie and Lew Wasserman Building, a $115.6 million project designed by Richard Meier & Partners Architects. Three floors of the six-story, 100,000-square-foot project will be dedicated to the patient care and research programs of the Jules Stein Eye Institute.
The remaining space will be occupied by the David Geffen School of Medicine’s Institute of Urologic Oncology and neurosurgery department.

From Left: Dr. Neil Martin, chair of the UCLA Department of Neurosurgery, Dr. Bartley Mondino, director of the Jules Stein Eye Institute, Casey Wasserman, CEO of the Wasserman Foundation, Edie Wasserman, grandmother of Casey Wasserman and wife of Lew Wasserman, UCLA Chancellor Gene Block, Michael Palladino, lead architect principal-in-charge, Richard Meier & Partners Architects Dr. Eugene Washington, vice chancellor of the UCLA Health Sciences and dean of the David Geffen School of Medicine at UCLA, Dr. Arie Belldegrun, director of the Institute of Urologic Oncology and Doumani Professor of Urologic Oncology at UCLA. View larger photo | UCLA Newsroom press release

Learn more about our clinical programs

Learn more about Patient Access to the Newest Drugs and Clinical Trials

UCLA is beginning clinical trials in bladder and prostate cancer, including, as part of a FDA-approved clinical trial, a study using High Intensity Focused Ultrasound (HIFU) for the treatment of locally recurring prostate cancer. HIFU is an exacting technique that aims sound waves at prostate tissue to destroy cancerous lesions.

Learn more about our Clinical Trial Program »

Contact Us

For information about the Institute of Urologic Oncology, call (310) 794-7700
Bookmark this site at www.iuo.ucla.edu

Request an appointment online »

UCLA Rated One of the Top Hospitals in the Nation